PHARMA EQUITY GROUP takes majority stake in OTIOM

Permira has reached an agreement to acquire a significant minority stake in Carne Group. The transaction facilitates the complete exit of Vitruvian Partners (who invested in 2021) and other minority shareholders. Crucially, the founder John Donohoe, the management team, and employees will retain the majority of the capital and voting control, ensuring continuity in governance. The partnership is intended to accelerate Carne's international expansion, specifically in the United States, and to fuel further development of its digital platform

TPG is in advanced negotiations to acquire Optum UK from UnitedHealth Group. This transaction follows UnitedHealth’s relatively short ownership of the asset, which it acquired in 2023 after an intensive regulatory review by the UK Competition and Markets Authority. The sale process, managed by Bank of America, attracted significant interest from top-tier private equity firms, including Blackstone, reflecting the asset’s status as a high-quality infrastructure-like software provider. The strategic rationale for TPG is a clear "buy-and-build" play, as the firm intends to explore a merger between Optum UK and Nextech, its US-based electronic medical record software provider

Asker Healthcare Group has signed a definitive agreement to acquire 80% of the shares in Finmed Group, marking its strategic entry into the French healthcare market. This transaction serves as a platform acquisition, providing the Swedish-based group with a robust foundation to expand its presence in one of Europe's largest medical device markets. The deal was structured to ensure management continuity, with Finmed's leadership, including Elie Fiani and Jean-Marc Soghomonian, remaining at the helm to drive the next phase of development

The management team of Excelya selected Eurazeo to invest as a minority partner with a ticket composed of a mix of equity (capped at 20%) and quasi-equity instruments, alongside a senior debt package. The transaction facilitated a partial liquidity event for the co-founding partner, who remains a minority shareholder, while providing the company with substantial firepower to pursue further international acquisitions. This partnership aims to consolidate Excelya's position as the leading independent CRO in Europe by targeting mid-sized acquisitions that complement its geographical footprint and therapeutic expertise

A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates.

Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe. The partnership will focus on product innovation (AI integration for planning) and potential strategic acquisitions to build a comprehensive HR platform for the healthcare sector

Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group. The strategic rationale is centered on the creation of a unified, AI‑driven “One Place for Health and Care” platform. Transcarent’s WayFinding experience, generative AI‑powered navigation, and complex‑care pathways in Cancer Care, Surgery Care, and Weight Health are combined with Accolade’s strengths in health advocacy, expert medical opinions (EMO), and virtual primary care

Kersia is acquiring the animal biosecurity cleaners and disinfectants business from Neogen® through an exclusive agreement. This strategic transaction marks a major entry for the French group into the North American swine and poultry markets, complementing its existing domestic presence in the ruminant sector. The acquisition is a transformative step for the group, doubling its American activity and positioning it among the top three global players in the agricultural hygiene and disinfection market

Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering. Under the new ownership structure, CEO Luca Borella retained his position and a significant minority stake. Ardian intends to leverage its global network and "Buy-and-Build" expertise to accelerate Masco's footprint in North America and Asia, while deepening its technological capabilities in the high-growth biologics and injectable drug sectors

PharmaCord has been acquired by a company backed by Permira following a definitive agreement signed in June 2024. The transaction introduces new capital to PharmaCord while the existing management team, led by founder and CEO Nitin Sahney, retains operational control and a significant equity position. The investment is subject to customary regulatory approvals and is anticipated to close in the fourth quarter of 2024. Financial advisers to PharmaCord were Centerview Partners, with legal counsel provided by Willkie Farr & Gallagher; Permira’s advisers included Jefferies LLC and Leerink Partners, and its legal counsel was Skadden, Arps, Slate, Meagher & Flom LLP